SCHEMBL18070713

SCHEMBL18070713

CCOC(=O)C(=O)c1ccc(-c2ccc(F)cc2)cc1CON1C(=O)c2ccccc2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
HTT P42858 2/20 0.37
TP53 P04637 1/20 0.37
MEN1 O00255 6/20 0.37
KMT2A Q03164 6/20 0.37
LMNA P02545 2/20 0.37
MAPT P10636 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
KDM4E B2RXH2 3/20 0.36
HPGD P15428 2/20 0.36
GAA P10253 2/20 0.36
ATM Q13315 1/20 0.36
ALOX12 P18054 1/20 0.36
CCR6 P51684 1/20 0.36
HKDC1 Q2TB90 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18070677 0.83 ALDH1A1 (0.40) ALDH1A1HTTMEN1KMT2ALMNA
SCHEMBL18070702 0.82 ALDH1A1 (0.42) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL18069874 0.80 MAPT (0.37) ALDH1A1HTTTP53MEN1KMT2A
SCHEMBL18069872 0.80 MAPT (0.49) ALDH1A1HTTTP53MEN1KMT2A
SCHEMBL18069845 0.78 MEN1 (0.39) ALDH1A1HTTMEN1KMT2ALMNA
SCHEMBL18070684 0.77 MAPT (0.46) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL18070698 0.74 PARP10 (0.42) ALDH1A1MEN1KMT2A
SCHEMBL9396285 0.74 ALDH1A1 (0.49) ALDH1A1HTTMEN1KMT2AMAPT
SCHEMBL18070694 0.73 MAPT (0.50) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL18070729 0.72 ALDH1A1 (0.39) ALDH1A1MEN1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10759769-B2 Glucosylceramide synthase inhibitors for the treatment of diseases BIOMARIN PHARMECEUTICAL INC (US) 2020-09-01 US disclosed
US-20190248754-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMECEUTICAL INC (US) 2019-08-15 US disclosed
EP-3268355-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARM INC (US) 2019-06-12 EP disclosed
US-10227312-B2 Glucosylceramide synthase inhibitors for the treatment of diseases BIOMARIN PHARMACEUTICAL INC. (US) 2019-03-12 US disclosed
US-20180044302-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. 2018-02-15 US disclosed
US-20180044302-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. 2018-02-15 US disclosed
WO-2016145153-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. (US) 2016-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10759769-B2 Glucosylceramide synthase inhibitors for the treatment of diseases GBA1, UGCG, GBA2 ALDH1A1 1342/4885HTT 1455/4885TP53 4578/4885
US-20180044302-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES GBA1, UGCG, GBA2 ALDH1A1 1342/4885HTT 1455/4885TP53 4578/4885
US-20190248754-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES GBA1, UGCG, GBA2 ALDH1A1 1342/4885HTT 1455/4885TP53 4578/4885
US-10227312-B2 Glucosylceramide synthase inhibitors for the treatment of diseases GBA1, UGCG, GBA2 ALDH1A1 1342/4885HTT 1455/4885TP53 4578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.